Terilyn J. Monroe - 01 Jan 2026 Form 4 Insider Report for Guardant Health, Inc. (GH)

Role
Chief People Officer
Signature
/s/ John G. Saia, as attorney-in-fact for Tarilyn J. Monroe
Issuer symbol
GH
Transactions as of
01 Jan 2026
Net transactions value
-$768,501
Form type
4
Filing time
05 Jan 2026, 18:01:07 UTC
Previous filing
03 Dec 2025
Next filing
09 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Monroe Terilyn J. Chief People Officer 3100 HANOVER STREET, PALO ALTO /s/ John G. Saia, as attorney-in-fact for Tarilyn J. Monroe 05 Jan 2026 0001652956

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GH Common Stock Options Exercise $0 +14,896 +71% $0.000000 35,886 01 Jan 2026 Direct
transaction GH Common Stock Options Exercise $0 +2,659 +7.4% $0.000000 38,545 01 Jan 2026 Direct
transaction GH Common Stock Tax liability $768,501 -7,524 -20% $102.14 31,021 01 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GH Performance-Based Restricted Stock Units Options Exercise $0 -14,896 -50% $0.000000 14,898 01 Jan 2026 Common Stock 14,896 $0.000000 Direct F2, F3
transaction GH Restricted Stock Units Options Exercise $0 -2,659 -12% $0.000000 18,615 01 Jan 2026 Common Stock 2,659 $0.000000 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2 This represents a performance-based restricted stock unit award granted on February 26, 2024, that a performance metric was achieved and that 33% of the shares subject to such award vested on March 1, 2025. 33% of the shares subject to the award vested on January 1, 2026, and the remaining 34% of the shares subject to the award will vest on January 1, 2027.
F3 Not applicable for Restricted Stock Units.
F4 This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.

Remarks:

Table I includes 70 shares acquired under Guardant Health's Employee Stock Purchase Plan on 11/14/2025.